ALMS.NASDAQAlumis INC
10-K/A: Alumis Inc. Files Amendment to 2024 Annual Report on Form 10-K/A
Sentiment:
Form 10-K/A Amendment
Alumis Inc. files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update certain disclosures.
Summary
- Alumis Inc. is filing Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024.
- The amendment includes information that was to be incorporated by reference from the proxy statement for the registrant's 2025 Annual Meeting of Stockholders.
- The amendment also updates certain information on the cover page of the 2024 Annual Report on Form 10-K and in the list of exhibits.
- The filing amends the cover page, Part III, Items 10 through 14, and Part IV, Item 15 of the 2024 Annual Report on Form 10-K.
- New certifications by the principal executive officer and principal financial officer are filed as exhibits to this amendment.
- No attempt has been made to modify or update other disclosures presented in the 2024 Annual Report on Form 10-K.
- The amendment does not reflect events occurring after March 19, 2025.
- As of April 17, 2025, the registrant had 47,222,419 shares of voting common stock and 7,184,908 shares of non-voting common stock outstanding.
- Based on the closing price as reported on the Nasdaq Global Select Market, the aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates on June 30, 2024 plus the aggregate amount of gross proceeds received from the registrant’s initial public offering from non-affiliates was approximately $165.4 million.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. The company is providing necessary updates and disclosures.
Related Party Transactions
- Foresite Labs Services Agreement: Alumis recognized $0.9 million in research and development expenses under the service agreement with Foresite Labs, LLC, an entity affiliated with Foresite Capital Management.
- Series C and Series C-1 Convertible Preferred Stock Financing: Alumis issued Series C preferred stock to AyurMaya Capital Management Fund, LP, entities affiliated with Baker Brothers Life Sciences, L.P., entities affiliated with Foresite Capital Management, Samsara BioCapital, LP, and venBio Global Strategic Fund IV, L.P.
- Concurrent Private Placement: AyurMaya Capital Management Fund, LP purchased $40.0 million in shares of Alumis common stock at the IPO price per share in a private placement transaction.
Key Dates
| Date | Description |
|---|---|
| 2021-05 | Mark Bradley appointed Chief Development Officer |
| 2021-06 | Zhengbin (Bing) Yao appointed to the Board |
| 2021-09 | Martin Babler appointed President, CEO, and Chairman of the Board |
| 2021-09 | David M. Goldstein appointed Chief Scientific Officer |
| 2021-09 | Roy Hardiman appointed Chief Business and Strategy Officer |
| 2022-01 | Sara Klein appointed Corporate Secretary and General Counsel |
| 2022-01 | Alan B. Colowick appointed to the Board |
| 2022-05 | John Schroer appointed Chief Financial Officer |
| 2022-08 | Sapna Srivastava appointed to the Board |
| 2022-09 | Jrn Drappa appointed Chief Medical Officer and Head of Research and Development |
| 2023-06 | Derrick Richardson appointed Senior Vice President of People and Culture |
| 2024-03 | Srinivas Akkaraju appointed to the Board |
| 2024-03 | Series C and Series C-1 Convertible Preferred Stock Financing |
| 2024-03-29 | Stock option repricing approved, reducing exercise price to $8.84 per share |
| 2024-06 | Patrick Machado appointed to the Board |
| 2024-06 | Board adopted a compensation recovery policy |
| 2024-06-07 | Julian Baker and Richard Gaster resigned from the Board |
| 2024-07-01 | Initial public offering (IPO) closed |
| 2024-07 | Concurrent Private Placement |
| 2024-09 | Sara Klein appointed Chief Legal Officer |
| 2025-01 | Roy Hardiman appointed Chief Business and Strategy Officer |
| 2025-02 | Board determined that the 2024 corporate goals were achieved at 105% |
| 2025-02-06 | Merger Agreement with ACELYRIN, Inc. dated |
| 2025-02 | Board adopted a non-employee director compensation policy |
| 2025-03-19 | Original 2024 Annual Report on Form 10-K filed with the SEC |
| 2025-04-01 | Date for security ownership information |
| 2025-04-17 | Date for outstanding shares of voting and non-voting common stock |
| 2025-04-23 | Date of executive officer and board member information |
| 2025-04-23 | Date of filing of Amendment No. 1 to Annual Report on Form 10-K/A |
Keywords
Form 10-K/A, amendment, annual report, directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, accountant fees, financial statements, Alumis Inc.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.